艾迪药业计划定增募资1.85亿元，用于收购子公司股权

Group 1 - The company plans to issue A-shares through a simplified procedure to raise no more than 185 million yuan for acquiring minority stakes in its subsidiary Nanjing Nanda Pharmaceutical and for supplementing working capital [1] - The company intends to acquire 22.2324% of Nanjing Nanda Pharmaceutical for approximately 130 million yuan, increasing its ownership from 51.1256% to 73.358% upon completion of the transaction, pending approval from market regulatory authorities [1] - The board of directors has approved relevant proposals but will not convene a shareholders' meeting immediately, planning to do so based on overall work arrangements [1] Group 2 - The company continues to advance the research and development of its products, including AD108 injection and ADB116 for injection [1]